Days after going public on the Hong Kong Stock Exchange, Insilico Medicine has struck a multi-year oncology drug discovery partnership with France’s Servier worth up to $888 million. The collaboration will focus on developing oncology therapies, by combining Insilico’s AI-driven drug discovery platforms with Servier’s global expertise in cancer drug development. Insilico pointed to its…
Lilly launches TuneLab, sharing AI drug-discovery models with biotechs
Eli Lilly launched “TuneLab,” an AI/ML platform that gives selected biotechs access to drug-discovery models trained on years of Lilly research data. Initial public partners include Circle Pharma and insitro. Lilly says the first release reflects more than $1B worth of internal data investment. Lilly says biotechs run its models locally on their own infrastructure…